Case report of ataxia telangiectasia

Authors

  • Raksha R. Kamat Department of Pediatrics, Government Medical College, Surat, Gujarat, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20230447

Keywords:

Ataxia-telangiectasia, Occulomotor apraxia, ATM gene, Lymphoreticular neoplasia

Abstract

Ataxia telangiectasia is rare inherited disorder characterized by progressive, neurodegenerative, variable immunodeficiency, celebral ataxia, ocular and cutaneous telangiectasia. They are prone for sinopulmonary infection also at risk of cancer development. Hallmark of disease is ataxia and telangiectasia. Incidence is 1 in 1,00,000 live births. 10-year-old presented to us with chief complaint of not able to Maintain balance and walk steady since 5 years of age. on examination bulbar telangiectasia was present. Also, dysdiadokinesia, past pointing, intention tremor was present. Magnetic resonance imaging (MRI) of the brain was done. Alpha fetoprotein was more than 1000. Vitamin E with balance exercise as supportive treatment starred. Ataxia begin during infancy when child start to walk, 2nd most hallmark of disease. In bulbar telangiectasia, average life span is 25-year-old. It is a multisystem genetic disorder. Death occurs due to cancer and infection. Counseling plays an important role as there is no cure for disease.

References

Border E, Sedwick RP. Ataxia — telangectasia; a familial syndrome of progressive cerebellar ataxia, oculo cutaneous telangectasia and Frequent pulmonary infection, Pediatrics, 1958;21:526-54 Abraham RT. cell cycle checkpoint signalling through the ATM and ATR kinases. Genes Dev. 2001;15:2177-96.

Kliegman R, Geme JS. Nelson Text Book of Pediatrics Twenty First Edition. Elsevier. 2019.

Lavin MF, Shiloh Y. The genetic defectin ataxia telangiectasia. Ann Rev Immunol. 1997;15:177-202.

Shiloh Y. ATM and related proteinkinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155-68.

Shiloh Y, Kastan MB. ATM. Genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209-54.

Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1:179-86.

Barlow C, Dennery PA, Shigenaga MK, Smith MA, Morrow JD, Roberts LJ, Wynshaw-Boris A, Levine RL. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci U S A. 1999;96(17):9915-9.

Reichenbach J, Schubert R, Schindler D, Müller K, Böhles H, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal. 2002;4(3):465-9.

Reliene R, Fischer E, Schiestl RH. Effect of Nacetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 2004;64:5148-53.

Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, Russo A, Mitchell JB, Wynshaw-Boris A. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet. 2004;13(16):1793-802.

Kamsler A, Daily D, Hochman A, Stern N, Shiloh Y, Rotman G, Barzilai A. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res. 2001;61(5):1849-54.

Syllaba L, Henner K: Contribution a l'independence de l'athetose double idiopathique et congenitale. Rev Neurol. 1926;1:541-62.

Menkes JH, Sarnat HB, Maria BL. Child Neurology, 7th edition. Philadelphia: Lippincott Williams & Wilkins. 2006.

Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998;102(1):98-100.

Regueiro JR, Porras O, Lavin M, Gatti RA. Ataxia-telengiectasia: a primary immunodeficiency revisited. Immunol Allerg Clin North Am. 2000;20:177-6.

Ayache R, Najjar MF, Obeid H, Pousse H, Gueddiche MN. Ataxia telangiectasia: Clinical and biological study in 17 cases. Ann Biol Clin. 1994;52:117-20.

Downloads

Published

2023-02-23

Issue

Section

Case Reports